Targeting Folate Receptor Reverses Colorectal Cancer’s Resistance to Immunotherapy in Mice
Colorectal cancer (CRC) is the third most common cancer worldwide. Although immune checkpoint blockade is promising, responses to the treatment have been limited: treatments such as anti-PD-1 have resulted in only 15% of patients experiencing substantial benefits.
Now, a new study shows that a receptor for folate sustains colorectal cancer’s ability to evade a form of cancer immunotherapy—and finds that targeting this receptor with an approved compound can restore the treatment’s cancer-killing power in mice. The data add to the understanding of what factors can shape colorectal cancer’s response to immunotherapy and suggest that integrating folate receptor-based treatments into existing regimens could improve outcomes in patients with treatment-resistant tumors.
This work is published in Science Translational Medicine in the paper, “Targeting cancer immune evasion with anti-FOLR1 antibody-drug conjugate potentiates anti-PD-1 efficacy in colorectal cancer.”
Colorectal cancer tumors possess many properties that stall immunotherapy’s ability to enhance anti-tumor immunity, including defects in the expression of MHC-1. Indeed, loss of MHC-I antigen presentation in tumor cells drives immune evasion and resistance to immune checkpoint blockade in colorectal cancer.
Previous research has connected folate receptor α (FOLR1) to more aggressive disease progression and poorer prognoses in various types of solid tumors. In this study, researchers conducted fluorescence-activated cell sorting–based CRISPR activation screens using a druggable genome library and identified folate receptor α (FOLR1) as a top negative regulator. In the study, they found that “high expression of FOLR1 predicted a poor ICB response, enhanced cancer stemness, and unfavorable patient outcomes.”
In addition, the team’s proteomic analyses revealed that “FOLR1 stabilized the lactyltransferase AARS1 (alanyl-tRNA synthetase 1), which lactylated signal transducer and activator of transcription 1 (STAT1) at lysine-193 (K193), facilitating its interaction with TCPTP (T cell protein-tyrosine phosphatase) and inducing STAT1 dephosphorylation at tyrosine-701.”
The group also tested the potential of mirvetuximab soravtansine, an approved antibody-drug conjugate that inhibits FOLR1. In vitro experiments revealed that FOLR1 indirectly impaired the activity of the STAT1 signaling pathway and dampened MHC-1 activity, which supported the cancer cells’ adaptability and prevented CD8+ T cells from engaging tumor cells.
However, mirvetuximab soravtansine restored anti-tumor immunity and resensitized colorectal cancer tumors to anti-PD-1 blockade in mice.
“Our findings support anti-FOLR1 [antibody-drug conjugate] as a clinically actionable approach to overcome immune evasion and unlock immunotherapy efficacy in [colorectal cancer],” the authors write.
The post Targeting Folate Receptor Reverses Colorectal Cancer’s Resistance to Immunotherapy in Mice appeared first on GEN - Genetic Engineering and Biotechnology News.
Apa Reaksi Anda?
Suka
0
Kurang Suka
0
Setuju
0
Tidak Setuju
0
Bagus
0
Berguna
0
Hebat
0
